Market Report Source

Overview

Introduction

Cytokinetics is the first company to systematically investigate the cytoskeleton and molecular motors as possible drug targets for cancer and cardiovascular diseases. The company applies proprietary technologies in the development of sophisticated multi-protein biochemical assays that mimic biological function.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company’s pipeline portfolio includes Ispinesib (SB-715992), a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death; SB-743921, a second novel KSP inhibitor for advanced solid tumors; GSK-923295, a novel small molecule therapeutic targeting centromere-associated protein E It recognizes revenues in the form of research and development revenues, which are earned under agreements with third parties/collaborators such as GSK, Amgen, and AstraZeneca for contract research and development activities, may include nonrefundable license fees, research and development funding, cost reimbursements and royalties. The company’s total revenues decreased at a CAGR of 27.6% during 2002-2006, from $11.4 million to $3.1 million. This represents an absolute total decline of -$8.3 million for total revenues. The company’s only contributor to revenue growth during 2002-2006 was license fees, collaboration revenues and other revenues.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Cytokinetics – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)

TABLES
Table 1: Cytokinetics – Key Facts
Table 2: Cytokinetics – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 3: Cytokinetics – Key Events Impacting Share Price Performance
Table 4: Cytokinetics – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 5: Cytokinetics – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: Cytokinetics – Balance Sheet, 2002-2006 ($ Mn)
Table 7: Cytokinetics – Cash Flow, 2002-2006 ($ Mn)
Table 8: Cytokinetics – Collaboration Products
Table 9: Cytokinetics – Forecast Sales, 2006-2010 ($ Mn)
Table 10: Cytokinetics – Key Competitors
Table 11: Cytokinetics – Key Clients
Table 12: Cytokinetics – Key Shareholders
Table 13: Cytokinetics – SWOT Analysis Summary
Table 14: Cytokinetics – Value Chain Analysis
Table 15: Cytokinetics – Scorecard
Table 16: Cytokinetics – Key Employees
Table 17: Cytokinetics – Financial and Operational Overview